30th annual BIO-Europe conference
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, proudly attended the 30th annual BIO-Europe conference held in Stockholm, Sweden, from 4th to 6th November 2024. BIO-Europe is Europe’s premier partnering event, bringing together over 5,700 attendees from more than 3,000 companies to drive innovation in the biotechnology and pharmaceutical sectors.
Representing Physiomics were Dr Mark Davies, Head of Quantitative Pharmacology and Data Science, and Hayley Close, Head of Business Development, who participated in over 20 meetings across two days. These discussions focused on establishing partnerships with decision-makers in the biotech industry, showcasing Physiomics’ expertise in modelling and simulation, data science, and biostatistics to support drug development.
BIO-Europe provided an excellent platform for Physiomics to engage with new and existing clients, aligning our capabilities with their needs to streamline development and accelerate innovation.
For more information about Physiomics’ services and partnerships visit www.physiomics.co.uk.
Enquiries:
Physiomics plc
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.